Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
Cellectar Biosciences (NASDAQ: CLRB) will report third quarter financial results for the period ended September 30, 2025 and provide a corporate update on Thursday, November 13, 2025 at 8:30 a.m. Eastern Time.
The company will host a conference call and webcast for investors and analysts; a replay of the corporate presentation will be available in the Events section of the company’s Investor Relations website.
Cellectar Biosciences (NASDAQ: CLRB) riferirà i risultati finanziari del terzo trimestre per il periodo terminato il 30 settembre 2025 e fornirà un aggiornamento aziendale giovedì 13 novembre 2025 alle 8:30 ora orientale.
L'azienda ospiterà una conference call e una trasmissione webcast per investitori e analisti; una replica della presentazione aziendale sarà disponibile nella sezione Eventi del sito delle Relazioni con gli Investitori dell'azienda.
Cellectar Biosciences (NASDAQ: CLRB) reportará los resultados financieros del tercer trimestre para el periodo terminado el 30 de septiembre de 2025 y proporcionará una actualización corporativa el jueves 13 de noviembre de 2025 a las 8:30 a.m. hora del Este.
La empresa organizará una llamada de conferencia y una transmisión web para inversionistas y analistas; una repetición de la presentación corporativa estará disponible en la sección Eventos del sitio de Relaciones con Inversionistas de la empresa.
Cellectar Biosciences (NASDAQ: CLRB)는 2025년 9월 30일에 종료되는 기간의 3분기 재무 실적을 발표하고 2025년 11월 13일 목요일에 기업 업데이트를 제공할 예정입니다.
회사는 투자자 및 분석가를 위한 컨퍼런스 콜과 웨비나를 주최할 것이며, 기업 발표의 재방송은 회사의 투자자 관계 웹사이트의 Events 섹션에서 볼 수 있습니다.
Cellectar Biosciences (NASDAQ : CLRB) affichera les résultats financiers du troisième trimestre pour la période se terminant le 30 septembre 2025 et fournira une mise à jour de l'entreprise le jeudi 13 novembre 2025 à 8 h 30, heure de l'Est.
La société organisera un appel-conférence et une diffusion Web pour les investisseurs et les analystes ; une révision de la présentation d'entreprise sera disponible dans la section Événements du site des Relations Investisseurs de la société.
Cellectar Biosciences (NASDAQ: CLRB) wird die Finanzergebnisse des dritten Quartals für den Zeitraum beendet am 30. September 2025 bekannt geben und am Donnerstag, dem 13. November 2025 um 8:30 Uhr Ostzeit ein Unternehmens-Update liefern.
Das Unternehmen wird eine Telefonkonferenz und einen Webcast für Investoren und Analysten ausrichten; eine Wiederholung der Unternehmenspräsentation wird im Bereich Veranstaltungen der Investor-Relations-Website des Unternehmens verfügbar sein.
Cellectar Biosciences (NASDAQ: CLRB) ستعلن عن نتائجها المالية للربع الثالث عن الفترة المنتهية في 30 سبتمبر 2025 وتقدم تحديثاً شركياً في يوم الخميس 13 نوفمبر 2025 الساعة 8:30 صباحاً بتوقيت شرق الولايات المتحدة.
ستستضيف الشركة مكالمة هاتفية جماعية وبثاً إلكترونياً للمستثمرين والمحللين؛ ستتوفر إعادة عرض العرض المؤسسي في قسم الفعاليات على موقع علاقات المستثمرين بالشركة.
- None.
- None.
FLORHAM PARK, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company will report financial results for the third quarter ended September 30, 2025, and provide a corporate update on November 13, 2025, at 8:30 a.m. Eastern Time.
| Conference Call & Webcast Details: | |
| Date: | Thursday, November 13, 2025 |
| Time: | 8:30 am Eastern Time |
| Toll Free: | 1-800-717-1738 |
| Conference ID: | 42734 |
| Webcast: | Click HERE |
A replay of the corporate presentation will be available on the Events section of the company’s Investor Relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical radiopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments that deliver improved efficacy and better safety.
The company’s product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope) for the treatment of hematologic and solid tumor cancers such as Waldenstrom’s macroglobulinemia (WM) and pediatric high grade gliomas; CLR 121125, an iodine-125 Auger-emitting program targeting solid tumors, such as triple negative breast, lung and colorectal cancers; CLR 121225, an actinium-225 based program targeting solid tumors with significant unmet need, such as pancreatic cancer; and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
Iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory WM and multiple myeloma (MM), non-Hodgkin’s lymphomas and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough Therapy, six Orphan Drug, five Rare Pediatric Drug and two Fast Track Designations for various cancer indications. The European Medicines Agency (EMA) has also granted PRIME and orphan drug designations for the treatment of WM.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook.
Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
FAQ
When will Cellectar Biosciences (CLRB) report Q3 2025 results?
How can investors join the Cellectar (CLRB) conference call on November 13, 2025?
What will Cellectar (CLRB) cover on the November 13, 2025 call?
Will there be a replay of the Cellectar (CLRB) November 13, 2025 presentation?
What time zone is the Cellectar (CLRB) November 13, 2025 call scheduled in?
What is the conference ID for Cellectar (CLRB) third quarter 2025 call?
